KJ26 KV25 KT26 KH25 KD26 Beater Mixer Coated KN256CBT KitchenAid KB26 KP26 KB25 KitchenAid Countertop Mixers


  1. Home
  2. KJ26 KV25 KT26 KH25 KD26 Beater Mixer Coated KN256CBT KitchenAid KB26 KP26 KB25
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
KitchenAid KN256CBT Coated Mixer Beater KD26 KH25 KT26 KV25 KJ26 KB26 KB25 KP26
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Bowl Capacity: 6 qt.
Suitable For: Countertop Mixer Capacity: 6qt.
Model:

KN256CBT

MPN:

WPW10672616

Country/Region of Manufacture: United States Brand:

KitchenAid

Color:

White

UPC:

0050946962665



published on tue nov 09 2021

KJ26 KV25 KT26 KH25 KD26 Beater Mixer Coated KN256CBT KitchenAid KB26 KP26 KB25 KitchenAid Countertop Mixers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

KJ26 KV25 KT26 KH25 KD26 Beater Mixer Coated KN256CBT KitchenAid KB26 KP26 KB25 KitchenAid Countertop Mixers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS